Europe’s benchmark FTSEurofirst 300 .FTEU3 ended up 0.1%, after touching seven-year highs ahead of the European Central Bank’s bond-purchase incentive that starts on Monday.
Tokyo’s Nikkei stock index .N225 rose 1.2 percent, ending higher for four successive weeks.
The MSCI world equity index .MIWD00000PUS, which tracks shares in 45 nations, shed 1.2 percent, to 424.71, the lowest close in three weeks.
Insights about U.S. Stocks that landed in the Active-Zone during Friday’s trade, are depicted underneath:
Geron Corporation (NASDAQ:GERN)’s shares declined -7.41%, and traded at $3.50. The Stock is active as 13.22M shares changed hands versus its average volume of 2.75M shares.
Geron Corporation (GERN), stated financial results for the fourth quarter and year ended December 31, 2014 and recent events.
Recent Corporation Events:
On October 31, 2014, the U.S. Food and Drug Administration (“FDA”) removed the full clinical hold on the corporation`s investigational new drug application for imetelstat. In addition, the FDA stated that the corporation`s projected clinical development plan for imetelstat that is focused on high-risk myeloid malignancies, such as myelofibrosis (“MF”), is acceptable.
On November 13, 2014, the corporation reached the Partnership Contract with Janssen to develop and commercialize imetelstat, the corporation`s telomerase inhibitor product candidate, worldwide for all indications in oncology, counting hematologic myeloid malignancies, and all other human therapeutics uses. Under the terms of the Partnership Contract, the corporation received an upfront payment of $35 million and is eligible to receive additional payments up to a potential total of $900 million for the achievement of development, regulatory and commercial milestones, in addition to royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities.
Development of imetelstat will proceed under a mutually agreed clinical development plan, which is predictable to comprise Phase 2 studies in MF and myelodysplastic syndromes (“MDS”) as initial studies, additional registration studies in MF and MDS, and exploratory Phase 2 and potential follow-on Phase 3 studies in acute myelogenous leukemia (“AML”). The corporation anticipates the Initial Phase 2 MF Study to be initiated in mid-2015 followed later by the Initial Phase 2 MDS Study to be initiated at the end of 2015. Development costs for these two studies will be shared between Janssen and Geron on a 50/50 basis.
Preceding to initiation of the Initial Phase 2 MF Study, both investigational new drug applications for imetelstat and the sponsorship of the MF Pilot Study being conducted by Dr. Tefferi will be transferred from Geron to Janssen. The primary transition activities related to the imetelstat program are predictable to be accomplished by mid-2015.
Geron is a clinical stage biopharmaceutical corporation focused on the development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Charles Schwab Corp (NYSE:SCHW), raised 2.75%, and traded at $31.04, hitting new 52-week high of $31.73. The Stock is active as13.20M shares changed hands versus its average volume of 6.72M shares. The stock has the beta value of 1.59, and its volatility for the week is 2.51%, while for the month it is 2.32%. The company has the market capitalization of $40.70B. The mean recommendation of analysts for this stock is 2.70.(where 1=Buy, 5=Sale).
The Charles Schwab Corporation, through its auxiliaries, provides wealth administration, securities brokerage, banking, money administration, and financial advisory services.
Halliburton Company (NYSE:HAL), declined -1.30%, and traded at $42.38. The Stock is active as 12.94M shares changed hands versus its average volume of 15.77M shares. The company holds the book value per share of 19.18, whereas cash per share is 2.70. Price to book value is estimated to be 2.21, while price to sale value is 1.10. Analysts mean recommendation for the stock is said to be 1.90 (where 1=Buy, 5=sale).
Halliburton Corporation provides a range of services and products to the upstream oil and natural gas industry worldwide. The corporation operates through two segments, Completion and Production, and Drilling and Evaluation.
Southwestern Energy Company (NYSE:SWN) dipped -3.63%, and traded at $23.65. The Stock is active as 12.58M shares changed hands versus its average volume of 9.55M shares.
Southwestern Energy Co. (SWN), stands among those stocks that totally missed the bull market Friday.
Formerly on February 27, Southwestern Energy Co., declared that its Board of Directors declared a quarterly dividend of $14.5833 per share on its 6.25% Series B Mandatory Convertible Preferred Stock, payable on April 15, 2015, to holders of record on April 1, 2015. This equates to $0.72917 for each depositary share, which represents a 1/20th interest in a share of the Series B preferred stock. The dividend is for the initial dividend period startning on January 21, 2015 and ending on April 14, 2015.
Southwestern Energy Corporation is an independent energy corporation whose wholly-owned auxiliaries are engaged in natural gas and oil exploration, development and production, natural gas gathering and marketing.
